The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Live Biotherapeutic Products, A Road Map for Safety Assessment
Open accessAbstract
Recent developments in the understanding of the relationship between the microbiota and its host have provided evidence regarding the therapeutic potential of selected microorganisms to prevent or treat disease. According to Directive 2001/83/EC, in the European Union (EU), any product intended to prevent or treat disease is defined as a medicinal product and requires a marketing authorization by competent authorities prior to commercialization. Even if the pharmaceutical regulatory framework is harmonized at the EU level, obtaining marketing authorisations for medicinal products remains very challenging for Live Biotherapeutic Products (LBPs). Compared to other medicinal products currently on the market, safety assessment of LBPs represents a real challenge because of their specific characteristics and mode of action. Indeed, LBPs are not intended to reach the systemic circulation targeting distant organs, tissues, or receptors, but rather exert their effect through direct interactions with the complex native microbiota and/or the modulation of complex host-microbiota relation, indirectly leading to distant biological effects within the host. Hence, developers must rely on a thorough risk analysis, and pharmaceutical guidelines for other biological products should be taken into account in order to design relevant non-clinical and clinical development programmes. Here we aim at providing a roadmap for a risk analysis that takes into account the specificities of LBPs. We describe the different risks associated with these products and their interactions with the patient. Then, from that risk assessment, we propose solutions to design non-clinical programmes and First in Human (FIH) early clinical trials appropriate to assess LBP safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regulatory requirements for the characterization of antimicrobial resistance genes (AMR) in probiotics and biopharmaceuticals are set out in regulatory documents from regulatory bodies such as the EFSA, FDA, and FAO/WHO [34,124,125].”
From Current Concepts in Probiotic Safety and Efficacy (2026) · cites this paper as [125]
Experimental — accuracy not yet measuredIn the citing paper
“This is important because while the safety standard for dietary supplements requires that they will reasonably expected to be safe under the labeled conditions of use, they do not need to be established as safe for more vulnerable patient populations.9”
From Emerging issues in probiotic safety: 2023 perspectives (2023) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., & Mele, M. C. (2019) · Microorganisms · doi:10.3390/microorganisms7010014 · Cited by 3,462
CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database
Jia, B., Raphenya, A. R., Alcock, B. P., Waglechner, N., Guo, P., Tsang, K. K., Lago, B. A., Dave, B. M., Pereira, S. K., Sharma, A. N., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1004 · Cited by 2,686
A framework for human microbiome research
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11209 · Cited by 2,650
The Comprehensive Antibiotic Resistance Database
McArthur, A. G., Waglechner, N., Nizam, F., Yan, A., Azad, M. A., Baylay, A. J., Bhullar, K., Canova, M. J., Pascale, G. D., Ejim, L. J., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00419-13 · Cited by 2,287
Gut/brain axis and the microbiota
Mayer, E. A., Tillisch, K., & Gupta, A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76304 · Cited by 1,503
ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes
Gupta, S. K., Padmanabhan, B. R., Diene, S. M., Lopez-Rojas, R., Kempf, M., Landraud, L., & Rolain, J.-M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01310-13 · Cited by 1,476
How informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334 · cited 3×
“Given this wider host-specificity, the translation of efficacy and safety signals from animals to humans is extremely difficult (20) since the likelihood for the conservation of LBP targets between species is very low.”
BackgroundPATRIC, the bacterial bioinformatics database and analysis resource
Wattam, A. R., Abraham, D., Dalay, O., Disz, T. L., Driscoll, T., Gabbard, J. L., Gillespie, J. J., Gough, R., Hix, D., Kenyon, R. W., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1099 · Cited by 1,258
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
Flagged first, then by citations
Research works printed but not linked: 17
- 2001, 2001/83 of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, 67
- 2016, Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information
- 2019, 3053E General monograph on Live Biotherapeutic Products.
- 1997, ICHE8 General Considerations For Clinical Trials
- 2008, Guideline on Human Cell-Based Medicinal Products–EMEA/CHMP/410869/2006
- Wayne, 2019, CLSI Performance Standards for Antimicrobial Susceptibility Testing.
- Hindler, 2016, CLSI Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.
- 2018, WHO list of Criticaly important Antimicrobials for Human Medicine (WHO CIA List)
- 2018, Critically Important Antimicrobials for Human Medicine 6th Revision 2018
- 2009, ICHQ8(R2) on Pharmaceutical Development
- 2011, ICHS6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
- 2010, 2010/63 of 22 September 2010 on the Protection of Animals Used for Scientific Purposes, 33
- 2018, ICHS11 Nonclinical Safety Testing in Support of Development of Paediatric Medicines–Draft Version Step 2
- 2008, Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling - EMEA/CHMP/203927/2005
- 2006, 1902/2006 of 20 December 2006 Amending Regulation 1901/2006 on Medicinal Products for Paediatric Use, 20
- 2017, ICHE11(R1) Clinical Investigation of Medicinal Products in the Paediatric Population
- 1993, ICHE7 Studies in Support of Special Populations: Geriatrics
Cited by
Sorted by citations
Items 101–121 of 121
Live biotherapeutics in cancer therapy
Mishra, R., Kumar, S. S., Panda, T. S., Mahapatra, S., & Prasad, P. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.002
A Microbial Odyssey: Reshaping Probiotic Destinies through Advanced Delivery Technologies
Zhang, A., Rong, Y., Gao, Y., Fan, G., Zhao, A., & Qi, S. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-10926-x
Recent advances of microbial medicine to prevent and treat cardiovascular disease
Mahajan, S., Anagha, N. K., & Banerjee, S. K. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.028
Friend and Foe: Microbes in Orchestrating Immunity and Shaping Infection Dynamics
Nair, A. V. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00709
ADVANCES IN PROBIOTIC DEVELOPMENT AND PARAMETERS FOR PHASE II CLINICAL TRIALS
ШОРАБАЕВ, Е. Ж., RATNIKOVA, I. A., ORAZYMBET, S. E., MIRALIMOVA, S. M., & Tleubekova, D. (2026) · МИКРОБИОЛОГИЯ ЖӘНЕ ВИРУСОЛОГИЯ · doi:10.53729/mv-as.2026.01.03
Gao, Y., Tong, T., Zeng, Z., Hou, K., Miao, D., Huang, C., & Xiong, R. (2026) · Journal of Bioresources and Bioproducts · doi:10.1016/j.jobab.2026.100249
Sherwani, M. K., Zainab, S. R., Khan, J., Ghazanfar, S., Hilal, F., Noor, R., & Tipu, M. K. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05396-5
Development strategies for engineered live biotherapeutic products for metabolic diseases
Yun, S., Choi, K.-S., Min, H., Jo, Y. K., & Jang, S. (2026) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2026.2653692 · Cited by 1
Murtazin, A. A., Islamgulov, A. K., & Malievsky, V. A. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203517
Liu, R., & Wang, J. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1797486
Molecular mechanisms involved in the anticancer activities of probiotics and postbiotics
Rocchetti, M. T., Mangieri, D., Spano, G., & Fiocco, D. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04411-2
Chen, W.-M., Sun, M.-Y., Ye, J., Tan, D.-C., Zhang, Z.-Y., & Liu, J. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1812973
Wu, J., Yang, Y., Li, T., Zhang, B., Chen, Z., Li, J., & Xiao, Y. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2026.08.002
Microbiome-Based Therapeutics in Oncology: Expanding Indications Beyond C. difficile
Al-Omari, A., Kheshman, A., Morkos, P., Davanzo, K., & Monday, L. (2026) · Onco · doi:10.3390/onco6030047
C, A. O., Narayanan, A., Vijayashree, R., Gurav, V. U., Menon, G., & Kottarath, S. K. (2026) · Next Materials · doi:10.1016/j.nxmate.2026.103643
Kaur, M., & Mishra, A. K. (2026) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-026-05300-6
Engineering electrospun living nanofibers for oral therapeutics
Ferrace, M. N., Ballarin, F. M., Rivero, G., Bruyère, J., Cabral, H., Cattoni, D. I., & Abraham, G. A. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.116263
Liang, Y., Ning, Z., Su, B., Liang, N., Zhu, F., & Sun, T. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111354
Microorganism-integrated microneedles: emerging biohybrid platforms for next-generation therapeutics
Jiang, W., Liu, Y., Seidi, F., & Xiao, H. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127609
Towards a sequential microbiome therapy for HPV-associated cervicovaginal dysbiosis
Molina, M. A., Zhang, Y., Steenbergen, R. D. M., Melchers, W. J. G., & Du, J. (2026) · Communications Biology · doi:10.1038/s42003-026-11208-6
Metadata
- Authors
- Rouanet, A., Bolca, S., Bru, A., Claes, I., Cvejic, H., Girgis, H., Harper, A., Lavergne, S. N., Mathys, S., Pane, M., Pot, B., Shortt, C., Alkema, W., Bezulowsky, C., Blanquet-Diot, S., Chassard, C., Claus, S. P., Hadida, B., Hemmingsen, C., Jeune, C., Lindman, B., Midzi, G., Mogna, L., Movitz, C., Nasir, N., Oberreither, M., Seegers, J. F. M. L., Sterkman, L., Valo, A., Vieville, F., & Cordaillat-Simmons, M.
- Affiliations
- Lallemand (France) (FR)
- Protexin (GB)
- Institut Mérieux (France) (FR)
- Probiotical (Italy) (IT)
- Vrije Universiteit Brussel (BE)
- Johnson & Johnson (United Kingdom) (GB)
- Nederlands Instituut Voor Zuivel Oonderzoek (NL)
- Ipsen (France) (FR)
- Université Clermont Auvergne (FR)
- Chr. Hansen (Denmark) (DK)
- PiLeJe (France) (FR)
- ORCID
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2020-06-19
- Volume
- 7
- Pages
- 237-237
- ISSN
- 2296-858X (ISSN-L)
- PMC
- PMC7319051
- OpenAlex
- W3036229416
- Cited by
- 120
- References
- 74
- Citations by year
- 2026: 30 · 2025: 22 · 2024: 18 · 2023: 9 · 2022: 21 · 2021: 18 · 2020: 2
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Agricultural and Biological Sciences › Food Science › Agricultural safety and regulations
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- live biotherapeutic products, safety assessment, risk analysis, host-microbiota interactions, microbiota-based therapy, drug approval, regulatory framework
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
